Infections in Hematology: Advances in Diagnosis, Management, and Prevention in Benign and Malignant Disorders

Infections remain a leading cause of morbidity and mortality in patients with hematologic disorders, ranging from benign cytopenias to aggressive hematologic malignancies. Despite recent advances in antimicrobial therapies, vaccination strategies, and supportive care, early diagnosis, risk stratification, and optimal management remain challenging. This Research Topic aims to consolidate the latest evidence on the epidemiology, pathogenesis, clinical presentation, diagnostics, prophylaxis, and therapeutic strategies for infections in patients with hematologic disorders. By fostering collaboration among clinicians and researchers worldwide, this collection seeks to identify unmet needs, highlight innovative approaches, and provide guidance for both common and rare infectious complications. Contributions will help improve patient outcomes and advance precision infection management in hematology.

This Research Topic aims to consolidate the latest evidence on the epidemiology, pathogenesis, clinical presentation, diagnostics, prophylaxis, and therapeutic strategies for infections in patients with hematologic disorders. By fostering collaboration among clinicians and researchers worldwide, this collection seeks to identify unmet needs, highlight innovative approaches, and provide guidance for both common and rare infectious complications. Contributions will help improve patient outcomes and advance precision infection management in hematology.

We invite original research, reviews, case reports, and perspective articles focusing on infectious complications in both benign and malignant hematologic disorders. Topics may include, but are not limited to:

• Epidemiology and risk factors for infections in hematologic patients

• Novel diagnostic methods and biomarkers for early detection

• Management of bacterial, viral, and fungal infections

• Antimicrobial stewardship in hematology

• Vaccination strategies and immune reconstitution

• Infection prevention in HSCT and CAR-T therapy recipients

• Real-world clinical outcomes and cost-effectiveness studies

Submissions should present high-quality research, systematic reviews, or insightful clinical perspectives that advance understanding and improve management of infections in this vulnerable population.

Keywords: hematology, infection, immunocompromised, benign disorders, malignant disorders, antimicrobial therapy, prevention

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.